AKT1 and colorectal cancer: Studies in lung and colorectal cancer have demonstrated that KRAS mutations are associated with reduced effects of PI3K/Akt/mTOR therapies.[46,47] A KRAS mutation was detected in 24% of cervical AC patients compared to only 3% of SCC and 3% of ASC patients.